MacroGenics Homepage
10:48 AM | February 04, 2012
In the News...
See what others are writing or saying about MacroGenics. Learn moreCollaborators
| Boehringer Ingelheim |
 |
| Boehringer Ingelheim entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas. These drug candidates will be based on MacroGenics’ Dual-Affinity Re-Targeting (DART™) platform and will be directed against up to ten combinations of molecular targets. Learn More |
| Green Cross (Korea) |
 |
| In July 2010, Green Cross entered into a collaboration agreement with MacroGenics for the exclusive development and commercialization of MGAH22 (anti-HER2 monoclonal antibody) in Korea. A multinational Phase I study will be conducted in both the US and Korea. |
| Pfizer Inc. |
 |
In October 2010, MacroGenics entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize DART products directed at two undisclosed cancer targets. These MacroGenics DART proteins will be used to redirect the body’s cell-destroying, immune effector cells against tumor cells. Learn More |
| Servier |
 |
| Under the terms of the agreement, MacroGenics retains full development and commercialization rights to MGA271 in North America, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world. Learn More |